# Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Source: https://onco.cc/trials/nct07405476/  
OnCo record `nct07405476` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of zanidatamab in colorectal cancer, run by Emory University, now recruiting.

## Summary

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment is a phase 2, interventional study registered as NCT07405476 by Emory University, with a registry enrolment figure of 38 participants, started 2026-04-07 and due to reach its primary completion in 2028-12-18. Interventions recorded: Zanidatamab; Resection; Patient Observation; Echocardiography Test; Multigated Acquisition Scan; Endoscopic Procedure; Computed Tomography; Magnetic Resonance Imaging; Biospecimen Collection; Biopsy Procedure; Digital Rectal Examination; Electronic Health Record Review. Conditions listed: Colon Carcinoma; Colorectal Carcinoma; Rectal Carcinoma; Stage I Colon Cancer AJCC v8; Stage I Colorectal Cancer AJCC v8; Stage I Rectal Cancer AJCC v8; Stage II Colon Cancer AJCC v8; Stage II Colorectal Cancer AJCC v8; Stage II Rectal Cancer AJCC v8; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8. Primary outcome: Rate of Complete and Major Pathologic Regression (Cohort 1); Radiologic Response (Cohort 2); Tumor Regression Grades (Cohort 2). Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed colon and/or rectal cancer planned for curative intent treatment at gastrointestinal clinics of Emory University's Winship Cancer Institute and collaborating centers". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07405476
- Phase: 2
- Setting: A Phase II Clinical Trial of Neoadjuvant Zanidatamab for HER2+ Localized Colorectal Cancer
- Sponsor: Emory University
- Enrolled: 38

## Sources

- ClinicalTrials.gov NCT07405476: https://clinicaltrials.gov/study/NCT07405476

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [HER2-amplified colorectal cancer](https://onco.cc/cancers/her2-amplified-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- drugs: [Zanidatamab](https://onco.cc/drugs/zanidatamab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07405476.json